Shares of InMode Ltd. (INMD) Have Risen Above Previous 52-Week High

September 21, 2021 11:54:18

InMode Ltd. (NASDAQ:INMD) traded at a new 52-week high today of $150.69. Approximately 188,000 shares have changed hands today, as compared to an average 30-day volume of 773,000 shares.

InMode Ltd. is currently priced 43.3% above its average consensus analyst price target of $84.73.

Over the past year, InMode Ltd. has traded in a range of $33.92 to $150.69 and is now at $149.39, 340% above that low.

InMode Ltd. provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women’s health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its products platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, Evolve, Evoke, and Morpheus8. The majority of its revenue comes from the United States.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: